RXi Pharma (RXII) P/E Ratio
P/E Ratio as of Dec 4, 2025: -6.06
Average-5.21
Median-5.19
Minimum-6.06
Maximum-4.84
-6.06
1.01 (20.00%)past month
The P/E ratio for RXi Pharma (RXII) is -6.06 as of Dec 4, 2025. This represents a increase of 60.32% compared to its 12-month average P/E ratio of -3.78. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
RXi Pharma P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
RXi Pharma’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing RXi Pharma to industry peers.
RXi Pharma P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
RXi Pharma’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing RXi Pharma to industry peers.
RXi Pharma (RXII) P/E Ratio Insights
See RXi Pharma’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in RXi Pharma (RXII)
Order type
Buy in
Order amount
Est. shares
0 shares
RXi Pharma (RXII) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Dec 1, 2025 | $1.50 | -5.23 |
| Nov 3, 2025 | $1.79 | -5.45 |
| Oct 1, 2025 | $1.69 | -5.15 |
| Sep 2, 2025 | $1.83 | -5.57 |
| Aug 1, 2025 | $1.66 | -4.24 |
| Jul 1, 2025 | $2.08 | -5.32 |
| Jun 2, 2025 | $1.58 | -4.04 |
| May 1, 2025 | $1.62 | -3.01 |
| Apr 1, 2025 | $1.09 | -2.02 |
| Mar 3, 2025 | $1.16 | -1.66 |
| Feb 3, 2025 | $1.48 | -2.11 |
| Jan 2, 2025 | $1.07 | -1.53 |
RXi Pharma (RXII) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -6.06 | +309.46% |
| 2024 | -1.48 | +114.49% |
| 2023 | -0.69 | -34.91% |
| 2022 | -1.06 | -74.58% |
| 2021 | -4.17 | +52.19% |
| 2020 | -2.74 | — |
FAQs About RXi Pharma (RXII) P/E ratio
The latest P/E ratio of RXi Pharma (RXII) is -6.06, as of Dec 4, 2025. This is calculated based on its current stock price and earnings per share (EPS).
RXi Pharma’s last 12-month average P/E ratio is -3.78, compared to its current P/E ratio of -6.06. This reflects a increase of 60.32%.
RXi Pharma’s current P/E ratio of -6.06 is higher than its last 12-month average P/E of -3.78. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
RXi Pharma’s average P/E ratio over the last 3 years is -1.95. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
RXi Pharma’s average P/E ratio over the last 5 years is -2.76. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.